To gather more data, Novo Nordisk, the manufacturer of Ozempic and Wegovy, and Eli Lilly, the maker of Mounjaro and Zepbound, are tracking pregnancy and postpartum health outcomes in women who used these medications at the time of conception
The Semaglutide Treatment Effect in People with Obesity (STEP) program evaluated the once-weekly administration of 2.4 mg subcutaneous semaglutide in people with obesity or overweight
Insurance may not cover semaglutide for PCOS because its not FDA-approved for that condition
52% of the semaglutide-treated test subjects achieved a weight loss response of greater than 5%, while a weight loss response of greater than 10% was achieved by 21% of the test subjects treated with the peptide
Benefit from ongoing premium support How it Works
The result, for most patients, is a significant reduction in hunger and caloric intake without the constant willpower battle that makes most diets fail